Ken Griffin Erytech Pharma S.A. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.0 - $1.22 $0 - $7,074
5,799 Added 53.66%
16,606 $0
Q1 2023

May 15, 2023
SELL
$0.34 - $1.38 $9,105 - $36,959
-26,782 Reduced 71.25%
10,807 $10,000
Q4 2022

Feb 14, 2023
BUY
$0.33 - $0.68 $6,404 - $13,197
19,408 Added 106.75%
37,589 $12,000
Q3 2022

Nov 14, 2022
SELL
$0.6 - $1.31 $31,266 - $68,265
-52,111 Reduced 74.14%
18,181 $10,000

About Erytech Pharma S.A.

ERYP Quotes by TradingView
  • Ticker ERYP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,018,600
  • Market Cap $16.8M
  • Description
  • ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of...
More about ERYP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email